ERBB2 and breast carcinoma: We further demonstrated that 1 μmol/L lapatinib treatment inhibited the phosphorylation of all tyrosine sites on HER2 in both sensitive and resistant breast cancer cells (Supplementary Fig. S3A and S3B).